News Results for GlaxoSmithKline (GSK)

GlaxoSmithKline and Innoviva said Thursday that the landmark IMPACT study published in the New England Journal of Medicine or NEJM showed significant benefits of Trelegy Ellipta for patients with...

Emma Walmsley, Chief Executive Officer, has re-invested 1,885 shares in the company on the 12th April 2018 at a price of 1439.99p. The Director now holds 514,916 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, has re-invested 1,987 shares in the company on the 12th April 2018 at a price of 1429.60p. The Director now holds 516,903 shares. Story provided by...

Simon Dingemans, Financial Director, has re-invested 1,818 shares in the company on the 12th April 2018 at a price of 1429.60p. The Director now holds 681,981 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, has re-invested 16,583 shares in the company on the 12th April 2018 at a price of 1429.60p. The Director now holds 513,031 shares. Story provided by...

Emma Walmsley, Chief Executive Officer, has re-invested 16,583 shares in the company on the 12th April 2018 at a price of 1429.60p. The Director now holds 513,031 shares. Story provided by...

Credit Suisse today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1450p (from 1300p). Story provided by StockMarketWire.com Broker...

Kepler Cheuvreux today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1400p (from 1360p). Story provided by StockMarketWire.com Broker...

HSBC today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 2030p. Story provided by StockMarketWire.com Broker Forecasts data provided by...

Weaker sterling kept the FTSE 100 flying high, which was also supported by miners and oil major Royal Dutch Shell (RDSB) as risk appetite returned among investors. Glencore (GLEN) advanced 3.2% to...

Global markets continued to recover as fears over a trade war between the US and China cooled. The FTSE jumped 1.9% higher to 7,018 around midday, supported by a rally in the mining sector....

GlaxoSmithKline Tuesday announced that it has reached an agreement with Novartis to buy Novartis' 36.5% stake in their consumer healthcare joint venture for $13bn. As a result of the transaction,...

The FTSE 100 was still in the red despite US equities starting to recover from Thursday's sell-off on trade war fears. An uplift in sterling against the dollar was bad news for UK blue-chips as...

GlaxoSmithKline said European authorities had offered a positive opinion on an HIV treatment developed by ViiV Healthcare, a company in which it holds a majority stake. The European Committee for...

Fears of a trade war after Donald Trump imposed $60bn worth of tariffs on Chinese imports to the US and a potential response from China weighed on global markets, including the FTSE 100. Across...

GlaxoSmithKline confirmed Friday that it has withdrawn from the race to buy Pfizer's Consumer Healthcare business. Emma Walmsley, Chief Executive Officer, GSK said: 'While we will continue to...

GlaxoSmithKline said Friday that the European Commission and Japanese Ministry of Health, Labour and Welfare approved Shingrix for the prevention of shingles and post-herpetic neuralgia in adults...

Morgan Stanley today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to equal weight (from underweight) and raised its price target to 1400p (from 1300p). Story provided by...

Societe Generale today reaffirms its sell investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1130p. Story provided by StockMarketWire.com Broker Forecasts data...

GlaxoSmithKline said it had presented positive results from a study at a gathering in Orlando that showed patients who switched to Nucala from Xolair experienced improved asthma control. The...

Emma Walmsley, Chief Executive Officer, exercised 21,096 shares in the company on the 16th February 2018 at a price of 0.00p. The Director now holds 61,947 shares representing 0.00% of the shares...

Emma Walmsley, Chief Executive Officer, sold post-exercise 9,918 shares in the company on the 16th February 2018 at a price of 1315.63p. The Director now holds 52,029 shares representing 0.00% of...

Simon Dingemans, Financial Director, exercised 29,465 shares in the company on the 16th February 2018 at a price of 0.00p. The Director now holds 513,246 shares. Story provided by...

Simon Dingemans, Financial Director, sold post-exercise 14,128 shares in the company on the 16th February 2018 at a price of 0.00p. The Director now holds 499,118 shares. NOTE: Sold to meet tax...

GlaxoSmithKline and Innoviva announced the submission of the landmark InforMing the PAthway of COPD Treatment (IMPACT) data to the European Medicines Agency to support an expanded label for...

Kepler Cheuvreux today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to hold (from reduce) and raised its price target to 1360p (from 1340p). Story provided by...

Berenberg today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1705p (from 1760p). Story provided by StockMarketWire.com Broker Forecasts data...

Beaufort Securities today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to buy (from long term buy) and raised its price target to 1500p (from 1450p). Story provided by...

The FTSE 100 fell 27 points, or 0.37%, to 7,254.19 on Thursday morning following further losses on Wall Street and continued global market volatility. Nanoco (NANO) was the biggest gainer on the...

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline announced Thursday that it filed a patent infringement litigation against Gilead Sciences over bictegravir in...

Dr Vivienne Cox, Non Executive Director, bought 416 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 1,897 shares representing 0.00% of the shares in...

Urs Rohner, Non Executive Director, bought 562 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 5,385 shares representing 0.00% of the shares in issue....

Manvinder Banga, Non Executive Director, bought 2,250 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 15,536 shares representing 0.00% of the shares in...

Sir Philip Hampton, Chairman, bought 3,423 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 33,817 shares representing 0.00% of the shares in issue....

Sir Philip Hampton, Chairman, bought 3,423 shares in the company on the 7th February 2018 at a price of 1278.00p. The Director now holds 33,817 shares representing 0.00% of the shares in issue....

GlaxoSmithKline boosted its annual profit on buoyant demand for respiratory and HIV treatments, flu vaccines and consumer pain killers. Adjusted operating profit, the company's preferred measure,...

GlaxoSmithKline's meningitis B vaccine Bexsero received breakthrough therapy designation from the US Food and Drug Administration for prevention of invasive meningococcal disease in children two to...

UK equities remained in favour thanks to better than anticipated economic data with retailers and utilities enjoying uplift in value. The FTSE 100 closed 0.6% higher at 7,665. The UK economy grew...

GlaxoSmithKline has received favorable rulings from European regulators regarding two separate treatments, one for shingles and the other for asthma. The European Medicines Agency's Committee for...

GlaxoSmithKline has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for a labelling update to Relvar Ellipta in patients...

Liberum Capital today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1630p (from 1760p). Story provided by StockMarketWire.com

Barclays Capital today upgrades its investment rating on GlaxoSmithKline PLC (LON:GSK) to overweight (from equal weight) and raised its price target to 1650p (from 1450p). Story provided by...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1500p. Story provided by StockMarketWire.com

Exane BNP Paribas today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1580p. Story provided by StockMarketWire.com

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1440p (from 1380p). Story provided by StockMarketWire.com

GlaxoSmithKline has received approval by the US Food and Drug Administration of labelling changes to remove the boxed warning from inhaled corticosteroid (ICS) / long-acting beta agonist (LABA)...

Dr Patrick Vallance, Executive Director, sold 52,974 shares in the company on the 18th December 2017 at a price of 1309.78p. The Director now holds 139,357 shares representing 0.00% of the shares...

GlaxoSmithKline has transferred 38,600,000 ordinary shares from treasury to BNY Mellon, the depositary of the company's American depositary receipts programme, to procure the issuance and transfer...

Citigroup today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1400p. Story provided by StockMarketWire.com

GlaxoSmithKline has presented promising new data from the dose expansion phase of the DREAMM-1 study of GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug...

GlaxoSmithKline has announced that new data from a phase III clinical study supports the safety and efficacy of Shingrix ((Zoster Vaccine Recombinant, Adjuvanted) in preventing shingles (herpes...

Simon Dingemans, Financial Director, bought 238 shares in the company on the 1st December 2017 at a price of 1131.00p. The Director now holds 482,810 shares. Story provided by...

Morgan Stanley today reaffirms its underweight investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1400p (from 1450p). Story provided by StockMarketWire.com

Today ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline , with Pfizer and Shionogi as shareholders, announced the start of HPTN 084, a phase III study to evaluate...

A fall in the price of copper weighed on the mining sector, with Antofagasta (ANTO) cheapening 3.7% to 942.3p and Anglo American (AAL) dropping 1.7% to £14.36. Copper declined 1% to $3.13 per...

A positive broker note on GlaxoSmithKline (GSK) from UBS provided the stock with a boost as the shares were lifted 1.8% to £13.21. Utility stocks also gained positive momentum as National Grid...

GlaxoSmithKline has filed a supplemental new drug application with the US Food and Drug Administration for the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol). The...

ViiV Healthcare, the global specialist HIV company, majority-owned by GlaxoSmithKline, with Pfizer and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1450p (from 1540p). Story provided by StockMarketWire.com

Societe Generale today reaffirms its sell investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1075p. Story provided by StockMarketWire.com

GlaxoSmithKline has announced that Dr Patrick Vallance, President, R&D, has will be leaving the company to become the UK Government's Chief Scientific Adviser and Head of the Government's...

Beaufort Securities today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1450p (from 1800p). Story provided by StockMarketWire.com

Berenberg today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1760p (from 1835p). Story provided by StockMarketWire.com

Fitch Ratings has affirmed GlaxoSmithKline's long-term issuer default rating at 'A' with stable outlook. Fitch has also affirmed the senior unsecured rating at 'A' for the debt issued by...

GlaxoSmithKline's investigational BCMA antibody-drug conjugate has received breakthrough therapy designation from the US Food and Drug Administration for relapsed and refractory multiple myeloma....

GlaxoSmithKline and Innoviva have confirmed positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist fixed-dose combination, Anoro...

Kepler Cheuvreux today reaffirms its reduce investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1340p (from 1520p). Story provided by StockMarketWire.com

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1540p (from 1700p). Story provided by StockMarketWire.com

Barclays Capital today reaffirms its equal weight investment rating on GlaxoSmithKline PLC (LON:GSK) and set its price target at 1450p. Story provided by StockMarketWire.com

Deutsche Bank today reaffirms its hold investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1500p (from 1610p). Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1330p (from 1570p). Story provided by StockMarketWire.com

The US Centres for Disease Control and Prevention's advisory committee on immunisation practices has voted in favour of three recommendations for the use of GlaxoSmithKline's Shingrix for the...

Sir Roy Anderson, Non Executive Director, bought 473 shares in the company on the 25th October 2017 at a price of 1518.00p. The Director now holds 234,820 shares representing 0.00% of the shares in...

Dr Vivienne Cox, Non Executive Director, bought 350 shares in the company on the 25th October 2017 at a price of 1518.00p. The Director now holds 1,481 shares representing 0.00% of the shares in...

Urs Rohner, Non Executive Director, bought 473 shares in the company on the 25th October 2017 at a price of 1518.00p. The Director now holds 4,823 shares representing 0.00% of the shares in issue....

Stronger than expected UK growth boosted the pound and weakened the dollar, which made the majority of FTSE 100's overseas earners less appealing to investors. The FTSE 100 fell 1.1% to 7,444.76...

Sir Philip Hampton, Chairman, bought 2,882 shares in the company on the 25th October 2017 at a price of 1518.00p. The Director now holds 30,394 shares representing 0.00% of the shares in issue....

Sir Philip Hampton, Chairman, bought 2,882 shares in the company on the 25th October 2017 at a price of 1518.00p. The Director now holds 30,394 shares representing 0.00% of the shares in issue....

GlaxoSmithKline (GSK) has reported an increase in total operating profit for the third quarter to £1,877m, compared to £1,431m in Q3 2016. Group turnover increased 4% AER (2% CER) to £7,843m,...

Emma Walmsley, Chief Executive Officer, has re-invested 9,617 shares in the company on the 12th October 2017 at a price of 1527.50p. The Director now holds 37,372 shares representing 0.00% of the...

Simon Dingemans, Financial Director, has re-invested 8,087 shares in the company on the 12th October 2017 at a price of 1527.50p. The Director now holds 480,411 shares. Story provided by...

Dr Patrick Vallance, Executive Director, has re-invested 9,295 shares in the company on the 12th October 2017 at a price of 1527.50p. The Director now holds 36,322 shares representing 0.00% of the...

The FTSE slid lower to 7,526 despite rising commodity prices as weaker utility stocks offset a rally in miners. National Grid (NG.) and United Utilities (UU.) retreated by up to 1.7%. Brent crude...

Unrest in the Middle East sparked a rally in the price of Brent crude oil, up 1.4% to $58 per barrel. The stronger oil price was matched by stronger copper prices which climbed 2.6% to $3.20 per...

Emma Walmsley, Chief Executive Officer, has re-invested 263 shares in the company on the 12th October 2017 at a price of 1524.25p. The Director now holds 27,755 shares representing 0.00% of the...

Dr Patrick Vallance, Executive Director, has re-invested 131 shares in the company on the 12th October 2017 at a price of 1524.25p. The Director now holds 27,027 shares representing 0.00% of the...

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price target to 1700p (from 1675p). Story provided by StockMarketWire.com

GlaxoSmithKline's vaccine, Shingrix, has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older. Shingrix is a non-live, recombinant subunit...

Dr Patrick Vallance, Executive Director, has re-invested 2,520 shares in the company on the 12th October 2017 at a price of 1526.59p. The Director now holds 26,896 shares representing 0.00% of the...

Emma Walmsley, Chief Executive Officer, has re-invested 409 shares in the company on the 12th October 2017 at a price of 1526.59p. The Director now holds 27,492 shares representing 0.00% of the...

Simon Dingemans, Financial Director, has re-invested 794 shares in the company on the 12th October 2017 at a price of 1526.59p. The Director now holds 472,324 shares. Story provided by...

Liberum Capital today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1760p (from 1900p). Story provided by StockMarketWire.com

GlaxoSmithKline and Innoviva have announced positive headline results from an IMPACT which showed that single inhaler triple therapy Trelegy Ellipta reduced chronic obstructive pulmonary disease...

Story provided by StockMarketWire.com

Oil giants BP (BP.) and Royal Dutch Shell (RDSB) boosted the FTSE 100 thanks to stable oil prices. Brent crude oil advanced 0.6% to $55.84 per barrel. Gold and copper were stable at $1,305 per...

GlaxoSmithKline has announced that the US Food and Drug Administration's vaccines and related biological products advisory committee has voted unanimously that the data support the efficacy and...

Story provided by StockMarketWire.com

JP Morgan Cazenove today reaffirms its neutral investment rating on GlaxoSmithKline PLC (LON:GSK) and cut its price target to 1570p (from 1750p). Story provided by StockMarketWire.com

GlaxoSmithKline and Innoviva have announced that positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at the European...